Re-evaluating population-level screening recommendations to address increasing early-onset colorectal cancer rates in Australia: a modelling study☆

J.-B. Lew , J. Worthington , H. Ge , Q. Luo , E. Feletto , K. Canfell , T. Price , Cancer Council Australia Colorectal Cancer Screening Working Party
{"title":"Re-evaluating population-level screening recommendations to address increasing early-onset colorectal cancer rates in Australia: a modelling study☆","authors":"J.-B. Lew ,&nbsp;J. Worthington ,&nbsp;H. Ge ,&nbsp;Q. Luo ,&nbsp;E. Feletto ,&nbsp;K. Canfell ,&nbsp;T. Price ,&nbsp;Cancer Council Australia Colorectal Cancer Screening Working Party","doi":"10.1016/j.esmogo.2025.100136","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The National Bowel Cancer Screening Program (NBCSP) sends free immunochemical faecal occult blood tests (iFOBTs) to eligible Australians aged 50-74 every 2 years. Rising early-onset colorectal cancer (CRC) rates in people under 50 have raised questions around optimising the NBCSP, contributing to the rationale for updating Australian CRC screening guidelines. To support this, alternative screening age ranges and approaches were evaluated.</div></div><div><h3>Methods</h3><div>A microsimulation model was used to estimate the impact of 2-yearly iFOBT screening starting at age 40, 45 or 50 and/or stopping at 74, 79, or 84 in cohorts with rising incidence rates. Yearly iFOBT screening and 5-yearly stool biomarker testing were also analysed.</div></div><div><h3>Results</h3><div>Lowering screening start ages to 45 or 40 could reduce CRC mortality rates by 5% and 10%, respectively, while extending stop ages to 79 or 85 could reduce CRC mortality rates by 3% and 5%, respectively. Lowering the start age would be more cost-effective and have a more favourable balance of benefits to harms versus raising the stop age.</div></div><div><h3>Conclusion</h3><div>As early-onset CRC rates increase, lowering the screening start age could reduce CRC burden while remaining cost-effective and limiting harms. Based on these findings and implementation considerations, the Cancer Council Australia Colorectal Cancer Screening Working Party determined that 2-yearly iFOBT screening from age 45 to 74 was the most favourable. These analyses supported the 2023 <em>Clinical practice guidelines for the prevention, early detection and management of colorectal cancer: Population Screening</em>, which led to the NBCSP including people aged 45-49 on an opt-in basis from July 2024.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"7 ","pages":"Article 100136"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000056","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The National Bowel Cancer Screening Program (NBCSP) sends free immunochemical faecal occult blood tests (iFOBTs) to eligible Australians aged 50-74 every 2 years. Rising early-onset colorectal cancer (CRC) rates in people under 50 have raised questions around optimising the NBCSP, contributing to the rationale for updating Australian CRC screening guidelines. To support this, alternative screening age ranges and approaches were evaluated.

Methods

A microsimulation model was used to estimate the impact of 2-yearly iFOBT screening starting at age 40, 45 or 50 and/or stopping at 74, 79, or 84 in cohorts with rising incidence rates. Yearly iFOBT screening and 5-yearly stool biomarker testing were also analysed.

Results

Lowering screening start ages to 45 or 40 could reduce CRC mortality rates by 5% and 10%, respectively, while extending stop ages to 79 or 85 could reduce CRC mortality rates by 3% and 5%, respectively. Lowering the start age would be more cost-effective and have a more favourable balance of benefits to harms versus raising the stop age.

Conclusion

As early-onset CRC rates increase, lowering the screening start age could reduce CRC burden while remaining cost-effective and limiting harms. Based on these findings and implementation considerations, the Cancer Council Australia Colorectal Cancer Screening Working Party determined that 2-yearly iFOBT screening from age 45 to 74 was the most favourable. These analyses supported the 2023 Clinical practice guidelines for the prevention, early detection and management of colorectal cancer: Population Screening, which led to the NBCSP including people aged 45-49 on an opt-in basis from July 2024.
重新评估人群水平的筛查建议,以解决澳大利亚不断增加的早发性结直肠癌发病率:一项模型研究
背景:国家肠癌筛查计划(NBCSP)每两年向50-74岁的合格澳大利亚人免费发送免疫化学粪便隐血检查(iFOBTs)。50岁以下人群中早发性结直肠癌(CRC)发病率的上升引发了围绕优化NBCSP的问题,这有助于更新澳大利亚CRC筛查指南的基本原理。为了支持这一点,评估了其他筛查年龄范围和方法。方法采用微观模拟模型来评估在发病率上升的队列中,从40岁、45岁或50岁开始和/或在74岁、79岁或84岁停止2年iFOBT筛查的影响。每年的iFOBT筛查和5年的粪便生物标志物检测也进行了分析。结果将筛查起始年龄降至45岁和40岁分别可使结直肠癌死亡率降低5%和10%,将筛查终止年龄降至79岁和85岁分别可使结直肠癌死亡率降低3%和5%。与提高终止年龄相比,降低起始年龄将更具成本效益,在利与害之间取得更有利的平衡。结论随着早发性结直肠癌发病率的增加,降低筛查起始年龄可减轻结直肠癌负担,同时保持成本效益并限制危害。基于这些发现和实施考虑,澳大利亚癌症委员会结直肠癌筛查工作组确定45岁至74岁的2年一次iFOBT筛查是最有利的。这些分析支持了2023年预防、早期发现和管理结直肠癌的临床实践指南:人群筛查,这使得NBCSP从2024年7月开始纳入45-49岁的人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信